Can nivolumab dosage be adjusted based on patient's weight?

Can nivolumab dosing be based on a patient’s weight?

Nivolumab dosing is generally not adjusted by body weight. It is commonly given as a fixed dose or as a body-surface-area (BSA)–based dose depending on the approved regimen and cancer type, rather than a simple weight-based mg/kg calculation [1][2].

What dosing methods are used for nivolumab (fixed dose vs BSA)?

Depending on the indication, nivolumab is prescribed either:
- As a fixed flat dose (same amount for patients regardless of weight), or
- Based on body surface area (BSA), which uses height and weight to calculate dosing [1][2]

This means clinicians may use the patient’s weight indirectly if the prescribed regimen uses BSA, but it is not typically a direct weight-based adjustment (mg/kg).

When might a clinician change dosing in practice?

Even though standard nivolumab dosing is not usually weight-adjusted, dosing can be modified for other reasons, such as treatment tolerance or immune-related adverse events, which may lead to dose interruption or discontinuation rather than changing the dose based on weight [1].

Where to check the exact dosing rule?

The correct approach depends on the specific product label and indication (and sometimes the formulation and schedule). The nivolumab prescribing information for that indication provides the dosing method (fixed dose vs BSA) and the allowed modifications for safety [1][2].

Sources

1. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
   
2. https://www.ema.europa.eu/en/medicines